Jason Gerberry
Stock Analyst at B of A Securities
(4.31)
# 371
Out of 5,148 analysts
166
Total ratings
63.33%
Success rate
11.88%
Average return
Main Sectors:
Stocks Rated by Jason Gerberry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $263 → $275 | $190.46 | +44.39% | 7 | Feb 25, 2026 | |
| HRMY Harmony Biosciences Holdings | Maintains: Underperform | $32 → $28 | $28.90 | -3.11% | 3 | Feb 25, 2026 | |
| ALKS Alkermes | Maintains: Neutral | $33 → $34 | $30.25 | +12.40% | 10 | Feb 20, 2026 | |
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $27.26 | +2.71% | 5 | Dec 15, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $62 → $81 | $64.33 | +25.91% | 4 | Dec 9, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $86 → $97 | $81.96 | +18.35% | 7 | Dec 9, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $29 → $32 | $33.77 | -5.24% | 15 | Dec 9, 2025 | |
| OCS Oculis Holding AG | Maintains: Buy | $30 → $29 | $28.61 | +1.36% | 4 | Nov 13, 2025 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $28 → $32 | $21.01 | +52.31% | 2 | Aug 26, 2025 | |
| IMVT Immunovant | Maintains: Buy | $33 → $30 | $27.75 | +8.11% | 6 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $49 | $11.81 | +314.90% | 2 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $173 → $176 | $166.38 | +5.78% | 6 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 → $1 | $2.31 | -56.71% | 4 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $23 | $30.94 | -25.66% | 2 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $46 | $41.03 | +12.11% | 3 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $157 → $137 | $61.98 | +121.04% | 9 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $11 → $10 | $15.70 | -36.31% | 3 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $23.88 | +25.63% | 2 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $100 | $114.05 | -12.32% | 5 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $24 | $9.79 | +145.15% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $41 → $31 | $34.09 | -9.06% | 6 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $600 → $550 | $1.19 | +46,118.49% | 3 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $42.55 | +31.61% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $500 | $1,017.97 | -50.88% | 15 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $2.65 | +239.62% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $37 → $25 | $7.19 | +247.71% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $5 | $1.37 | +264.96% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $27 | $5.95 | +353.78% | 4 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $1.65 | +1,112.12% | 1 | Jul 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $100 | $5.37 | +1,762.20% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $95 | $234.26 | -59.45% | 10 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $62.34 | -3.75% | 7 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $90 | $121.41 | -25.87% | 11 | Oct 17, 2019 |
Jazz Pharmaceuticals
Feb 25, 2026
Maintains: Buy
Price Target: $263 → $275
Current: $190.46
Upside: +44.39%
Harmony Biosciences Holdings
Feb 25, 2026
Maintains: Underperform
Price Target: $32 → $28
Current: $28.90
Upside: -3.11%
Alkermes
Feb 20, 2026
Maintains: Neutral
Price Target: $33 → $34
Current: $30.25
Upside: +12.40%
Pfizer
Dec 15, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $27.26
Upside: +2.71%
Arrowhead Pharmaceuticals
Dec 9, 2025
Maintains: Buy
Price Target: $62 → $81
Current: $64.33
Upside: +25.91%
Ionis Pharmaceuticals
Dec 9, 2025
Maintains: Buy
Price Target: $86 → $97
Current: $81.96
Upside: +18.35%
Teva Pharmaceutical Industries
Dec 9, 2025
Maintains: Buy
Price Target: $29 → $32
Current: $33.77
Upside: -5.24%
Oculis Holding AG
Nov 13, 2025
Maintains: Buy
Price Target: $30 → $29
Current: $28.61
Upside: +1.36%
Amphastar Pharmaceuticals
Aug 26, 2025
Maintains: Neutral
Price Target: $28 → $32
Current: $21.01
Upside: +52.31%
Immunovant
Aug 12, 2025
Maintains: Buy
Price Target: $33 → $30
Current: $27.75
Upside: +8.11%
Aug 12, 2025
Maintains: Buy
Price Target: $50 → $49
Current: $11.81
Upside: +314.90%
Aug 5, 2025
Maintains: Buy
Price Target: $173 → $176
Current: $166.38
Upside: +5.78%
Jun 30, 2025
Downgrades: Underperform
Price Target: $3 → $1
Current: $2.31
Upside: -56.71%
Jun 11, 2025
Maintains: Buy
Price Target: $25 → $23
Current: $30.94
Upside: -25.66%
Jun 5, 2025
Maintains: Neutral
Price Target: $45 → $46
Current: $41.03
Upside: +12.11%
Apr 1, 2025
Maintains: Buy
Price Target: $157 → $137
Current: $61.98
Upside: +121.04%
Feb 28, 2025
Maintains: Underperform
Price Target: $11 → $10
Current: $15.70
Upside: -36.31%
Jan 9, 2025
Reiterates: Buy
Price Target: $30
Current: $23.88
Upside: +25.63%
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $100
Current: $114.05
Upside: -12.32%
Sep 10, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $9.79
Upside: +145.15%
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $34.09
Upside: -9.06%
Mar 25, 2024
Maintains: Buy
Price Target: $600 → $550
Current: $1.19
Upside: +46,118.49%
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $42.55
Upside: +31.61%
May 24, 2023
Maintains: Buy
Price Target: $450 → $500
Current: $1,017.97
Upside: -50.88%
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $2.65
Upside: +239.62%
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $7.19
Upside: +247.71%
Dec 2, 2021
Downgrades: Underperform
Price Target: $45 → $5
Current: $1.37
Upside: +264.96%
Mar 24, 2021
Downgrades: Underperform
Price Target: $27
Current: $5.95
Upside: +353.78%
Jul 16, 2020
Initiates: Neutral
Price Target: $20
Current: $1.65
Upside: +1,112.12%
Jul 15, 2020
Downgrades: Neutral
Price Target: $170 → $100
Current: $5.37
Upside: +1,762.20%
May 18, 2020
Reinstates: Neutral
Price Target: $95
Current: $234.26
Upside: -59.45%
Oct 17, 2019
Reinstates: Buy
Price Target: $60
Current: $62.34
Upside: -3.75%
Oct 17, 2019
Reinstates: Neutral
Price Target: $90
Current: $121.41
Upside: -25.87%